Summary
Personalised Medicine (PM) approaches, thanks to the latest technological advances notably in the fields of biomedical and digital technologies, prove their potential to improve healthcare and underpin more efficient and sustainable health systems.
PM is at the top of the European Commission research agenda, with funding devoted to projects along the entire value chain. In China, PM is attracting massive interest, with the government capitalising on its expertise in biotechnology, computing hardware and the ability to put in place the infrastructures for supporting large bioinformatics projects.
Turning PM into an opportunity for all citizens and patients requires the engagement of all stakeholders, in order to define common research and development approaches, standards, and priorities, and to scale up the collaboration at the International level. In order to respond to these challenges, the EU supports actions developed within the International Consortium for Personalised Medicine (ICPerMed).
IC2PerMed project will provide key solutions for enabling the convergence under ICPerMed consortium of European and Chinese stakeholders towards a common approach of PM research, innovation, development and implementation involving policy makers and healthcare beneficiaries, by:
- mapping policies, programmes, standards and initiatives related to PM in Europe in China for identifying the opportunities for research collaborations;
- structuring its developments upon an ecosystem of European and Chinese experts, collaborating in Working Groups centred on ICPerMed Action plan priorities;
- setting bridges with key organisms involved in the definition and implementation of PM and healthcare systems in both economic areas, both on benefits for coordinated approaches for research and on concrete developments taking place within and along the project;
- inserting its developments in international contexts, through ICPerMed and its involvement in relevant initiatives and networks.
PM is at the top of the European Commission research agenda, with funding devoted to projects along the entire value chain. In China, PM is attracting massive interest, with the government capitalising on its expertise in biotechnology, computing hardware and the ability to put in place the infrastructures for supporting large bioinformatics projects.
Turning PM into an opportunity for all citizens and patients requires the engagement of all stakeholders, in order to define common research and development approaches, standards, and priorities, and to scale up the collaboration at the International level. In order to respond to these challenges, the EU supports actions developed within the International Consortium for Personalised Medicine (ICPerMed).
IC2PerMed project will provide key solutions for enabling the convergence under ICPerMed consortium of European and Chinese stakeholders towards a common approach of PM research, innovation, development and implementation involving policy makers and healthcare beneficiaries, by:
- mapping policies, programmes, standards and initiatives related to PM in Europe in China for identifying the opportunities for research collaborations;
- structuring its developments upon an ecosystem of European and Chinese experts, collaborating in Working Groups centred on ICPerMed Action plan priorities;
- setting bridges with key organisms involved in the definition and implementation of PM and healthcare systems in both economic areas, both on benefits for coordinated approaches for research and on concrete developments taking place within and along the project;
- inserting its developments in international contexts, through ICPerMed and its involvement in relevant initiatives and networks.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/874694 |
| Start date: | 01-01-2020 |
| End date: | 31-12-2023 |
| Total budget - Public funding: | 2 135 187,00 Euro - 1 691 437,00 Euro |
Cordis data
Original description
Personalised Medicine (PM) approaches, thanks to the latest technological advances notably in the fields of biomedical and digital technologies, prove their potential to improve healthcare and underpin more efficient and sustainable health systems.PM is at the top of the European Commission research agenda, with funding devoted to projects along the entire value chain. In China, PM is attracting massive interest, with the government capitalising on its expertise in biotechnology, computing hardware and the ability to put in place the infrastructures for supporting large bioinformatics projects.
Turning PM into an opportunity for all citizens and patients requires the engagement of all stakeholders, in order to define common research and development approaches, standards, and priorities, and to scale up the collaboration at the International level. In order to respond to these challenges, the EU supports actions developed within the International Consortium for Personalised Medicine (ICPerMed).
IC2PerMed project will provide key solutions for enabling the convergence under ICPerMed consortium of European and Chinese stakeholders towards a common approach of PM research, innovation, development and implementation involving policy makers and healthcare beneficiaries, by:
- mapping policies, programmes, standards and initiatives related to PM in Europe in China for identifying the opportunities for research collaborations;
- structuring its developments upon an ecosystem of European and Chinese experts, collaborating in Working Groups centred on ICPerMed Action plan priorities;
- setting bridges with key organisms involved in the definition and implementation of PM and healthcare systems in both economic areas, both on benefits for coordinated approaches for research and on concrete developments taking place within and along the project;
- inserting its developments in international contexts, through ICPerMed and its involvement in relevant initiatives and networks.
Status
SIGNEDCall topic
SC1-HCO-01-2018-2019-2020Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Search
Organisations
-
| UNIVERSITA CATTOLICA DEL SACRO CUORE (Coördinator)
-
| BGI SHENZHEN LIFE SCIENCE RESEARCH INSTITUTION
-
| BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC)
-
| CANCER HOSPITAL OF CHINESE ACADEMYOF MEDICAL SCIENCES
-
| FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS
-
| FONDAZIONE TELETHON ETS
-
| GAC
-
| INNO TSD
-
| Steinbeis 2i GmbH of Steinbeis Innovation gGmbH
-
| TSINGHUA UNIVERSITY
-
| WORLD FEDERATION OF PUBLIC HEALTH ASSOCIATIONS